{"groups":[{"description":"One single-dose, pre-filled, disposable applicator of investigational product was to be administered intravaginally at home.","id":"FG000","title":"Generic Clindamycin Phosphate Vaginal Cream 2%"},{"description":"One single-dose, pre-filled, disposable applicator of Investigational product to be administered intravaginally at home.","id":"FG001","title":"Clindesse (Clindamycin Phosphate Vaginal Cream 2%)"},{"description":"One single-dose, pre-filled, disposable applicator of Investigational product was to be inserted intravaginally at home.","id":"FG002","title":"Vehicle Cream"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"5"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Pregnancy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"5"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"1"}],"type":"Prohibited medication"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}],"type":"Negative Nugent score at baseline"},{"reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"8"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"242"},{"groupId":"FG001","numSubjects":"240"},{"groupId":"FG002","numSubjects":"122"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"233"},{"groupId":"FG001","numSubjects":"236"},{"groupId":"FG002","numSubjects":"122"}],"comment":"Randomized participants who received the investigational product.","type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"199"},{"groupId":"FG001","numSubjects":"207"},{"groupId":"FG002","numSubjects":"107"}],"comment":"Randomized participants that applied the study dose, and returned for post-baseline evaluation visit","type":"mITT Population"},{"achievements":[{"groupId":"FG000","numSubjects":"164"},{"groupId":"FG001","numSubjects":"169"},{"groupId":"FG002","numSubjects":"84"}],"comment":"Randomized subjects that were compliant with study treatment, and completed the study.","type":"PP Population"},{"achievements":[{"groupId":"FG000","numSubjects":"190"},{"groupId":"FG001","numSubjects":"193"},{"groupId":"FG002","numSubjects":"99"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"52"},{"groupId":"FG001","numSubjects":"47"},{"groupId":"FG002","numSubjects":"23"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The populations for this study included the Safety Population, the Per-Protocol (PP) Population, and the Modified Intent-to-treat (mITT) Population."}